Cancer is not called the disease of the 21st century for nothing: every year in the world there are more than 12 million cancer patients, 7 million of whom die. The insidiousness of oncology is that in the early stages it does not hurt, and many people learn about the diagnosis either by accident or at stage III-IV.
It is not difficult to assess your risk of getting cancer now: it is enough to take a DNA test for oncogenetics. Sistema BioTech’s leading specialists have developed unique genetic tests that provide comprehensive solutions in the field of oncology.
The world’s leading scientists are working to understand the genetic mechanisms of tumor formation, and are also looking for the genes responsible for cancer formation. And such genes do exist: almost 15% of all malignant neoplasms are inherited. There are individual features of the genome of each person and features of the genome of each tumor. Analysis of these features will help to assess the risks of developing the disease and personalize treatment for an already existing disease. This area of medicine is called precision oncology. SBT has developed its own algorithms for analyzing genetic changes in tumors to evaluate molecular profiles.
Sistema-BioTech is developing new kits for molecular profiling of diseases.
Analysis of the client's biomaterial by DNA, RNA sequencing, transcriptome analysis
Development of machine learning programs for genomic data interpretation.
Molecular profiling panel kit for somatic tumors
Development of oncopharmacoplatforms for therapy selection
Development of test systems for IVD platforms by your order
Evaluation of the effectiveness of chemotherapy - personal selection of chemotherapy.
Genetic research by Sistema BioTech
can be divided into two major areas:
Predisposition to hereditary (congenital) forms of cancer in order to determine the risks of developing cancer.
For cancer patients for the selection of therapy, taking into account molecular genetic characteristics.
Diagnosis of oncology risks
Cancer risk assessment is the right strategy for those who care about their health and think about the future. Information about existing mutations gives an understanding of the risks of developing cancer, and also allows the patient to start diagnostic and preventive measures in time.
Sistema BioTech offers the following DNA tests:
Comprehensive genomic profiling of solid tumors
Determination of somatic mutations in the BRCA1, BRCA2, BRAF, EGFR, KRAS, NRAS genes
Determination of ALK, ROS1 gene rearrangements
Genomic profiling in oncohematological diseases
Study of germline mutations in the BRCA1 and BRCA2 genes
Complete comprehensive panel: hereditary cancer syndromes (study of germline mutations in more than 120 genes)
Comprehensive panel: colorectal cancer (includes genes such as APC, AXIN2, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53)
Comprehensive panel: breast and ovarian cancer (includes genes such as ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53)
DNA based personalized therapy selection in oncology
A genetic study will clarify the diagnosis, identify the features of the course of oncology, as well as foci or targets that you should pay attention to for successful treatment. Dealing with oncology, treatment must necessarily be comprehensive and personalized.
DNA test answers many questions:
Which drug will work best for this patient.
What should be done with in case of the aggressive course of the disease.
To place an order for a test system, fill out the form. Orders are accepted for legal entities and individuals.
Cookies are used to provide a simple and efficient service to the users, browsing the pages